224 related articles for article (PubMed ID: 27908312)
1. Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options.
Fredi M; Bartoli F; Cavazzana I; Ceribelli A; Carabellese N; Tincani A; Satoh M; Franceschini F
Clin Exp Rheumatol; 2017; 35(2):303-308. PubMed ID: 27908312
[TBL] [Abstract][Full Text] [Related]
2. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.
Valenzuela A; Chung L; Casciola-Rosen L; Fiorentino D
JAMA Dermatol; 2014 Jul; 150(7):724-9. PubMed ID: 24869801
[TBL] [Abstract][Full Text] [Related]
3. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
4. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
5. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.
Gunawardena H; Wedderburn LR; Chinoy H; Betteridge ZE; North J; Ollier WE; Cooper RG; Oddis CV; Ramanan AV; Davidson JE; McHugh NJ;
Arthritis Rheum; 2009 Jun; 60(6):1807-14. PubMed ID: 19479859
[TBL] [Abstract][Full Text] [Related]
7. Anti-NXP2 antibody-associated extensive subcutaneous calcinosis in adult-onset myositis.
Goulabchand R; Guilpain P; Cyteval C; Le Quellec A
Rheumatology (Oxford); 2017 Oct; 56(10):1661. PubMed ID: 28605526
[No Abstract] [Full Text] [Related]
8. Skin lesions in anti-Pm-Scl-70 positive systemic sclerosis-dermatomyositis overlap syndrome improve during local PUVA phototherapy.
Mohanna M; Distler O; Sprott H; Kündig T; French LE; Hofbauer G
Eur J Dermatol; 2013; 23(5):730-1. PubMed ID: 24126033
[No Abstract] [Full Text] [Related]
9. [Anti PM-Scl antibodies. Study of prevalence and of meaning].
Gaudin C; Fortenfant F; Adoue D; Beyne-Rauzy O
Rev Med Interne; 2006 Sep; 27(9):665-70. PubMed ID: 16797795
[TBL] [Abstract][Full Text] [Related]
10. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis.
Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Franceschini F; Quinzanini M; Tincani A; Ross SJ; Chan JY; Pauley BA; Chan EK; Satoh M
Arthritis Res Ther; 2012 Apr; 14(2):R97. PubMed ID: 22546500
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody.
Marie I; Lahaxe L; Benveniste O; Delavigne K; Adoue D; Mouthon L; Hachulla E; Constans J; Tiev K; Diot E; Levesque H; Boyer O; Jouen F
Br J Dermatol; 2010 Feb; 162(2):337-44. PubMed ID: 19845665
[TBL] [Abstract][Full Text] [Related]
12. [Idiopathic inflammatory myopathies with anti-PM-Scl antibodies: case series and literature review].
Marie I; Lahaxe L; Tiev K; Duval-Modeste AB; Vittecoq O; Levesque H; Jouen F
Rev Med Interne; 2010 Aug; 31(8):540-4. PubMed ID: 20510485
[TBL] [Abstract][Full Text] [Related]
13. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
14. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.
D'Aoust J; Hudson M; Tatibouet S; Wick J; ; Mahler M; Baron M; Fritzler MJ
Arthritis Rheumatol; 2014 Jun; 66(6):1608-15. PubMed ID: 24577935
[TBL] [Abstract][Full Text] [Related]
15. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.
De Lorenzo R; Pinal-Fernandez I; Huang W; Albayda J; Tiniakou E; Johnson C; Milisenda JC; Casal-Dominguez M; Corse AM; Danoff SK; Christopher-Stine L; Paik JJ; Mammen AL
Neurology; 2018 Jun; 90(23):e2068-e2076. PubMed ID: 29728522
[TBL] [Abstract][Full Text] [Related]
16. Anti-PM-Scl antibody in patients with systemic sclerosis.
Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
[TBL] [Abstract][Full Text] [Related]
17. Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.
Albayda J; Pinal-Fernandez I; Huang W; Parks C; Paik J; Casciola-Rosen L; Danoff SK; Johnson C; Christopher-Stine L; Mammen AL
Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1771-1776. PubMed ID: 28085235
[TBL] [Abstract][Full Text] [Related]
18. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.
Ishikawa A; Muro Y; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Jul; 51(7):1181-7. PubMed ID: 22427409
[TBL] [Abstract][Full Text] [Related]
19. Anti-PM/Scl antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature.
Kohara A; Yanaba K; Muro Y; Ito H; Nakagawa H; Noda K; Kurosaka D
Int J Rheum Dis; 2017 Dec; 20(12):2186-2189. PubMed ID: 28185425
[No Abstract] [Full Text] [Related]
20. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.
Lazzaroni MG; Marasco E; Campochiaro C; DeVries-Bouwstra J; Gonzalez-Perez MI; Rojas-Serrano J; Hachulla E; Zanatta E; Barsotti S; Furini F; Triantafyllias K; Abignano G; Truchetet ME; De Luca G; De Langhe E; Hesselstrand R; Ingegnoli F; Bertoldo E; Smith V; Bellando-Randone S; Poormoghim H; Colombo E; Ceribelli A; Furloni A; Zingarelli S; Cavazzana I; Franceschini F; Del Galdo F; Denton CP; Cavagna L; Distler O; Allanore Y; Airò P;
Rheumatology (Oxford); 2021 Nov; 60(11):5028-5041. PubMed ID: 33580257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
